High-dose hemodiafiltration (HDF) produced substantially better survival compared with conventional, high-flux hemodialysis in people with CKD or end-stage kidney disease.
What is Hemodiafiltration?
Hemodiafiltration is a newer technology that relies not only on diffusion but also introduces convection, allowing for more efficient removal of larger and medium-sized water-soluble molecules.
In a recent report, MD, PhD, Peter J. Blankestijn, said at the European Renal Association Congress, a randomized, multicenter get a trial of 1360 patients treated for a median of 30 months.The results show that high-dose HDF, with a convection volume of greater than 23L/session, improved overall survival by 23% compared with normal hemodialysis, a significant difference for the study's primary endpoint.
However, the results were concurrently published in the “New England Journal of Medicine.” Similarly, Dr. Blankestijn, a senior nephrologist at the University Medical Center in Utrecht, The Netherlands said, this is the first time in decades that a change in the basic concept of dialysis proved to be clinically meaningful, and cool.
Cost Barrier in the US
One expert said, Hemodiafiltration (HDF) is the treatment which has had little US approval until now may remain unavailable to most patients given the tight budgets faced by US medical centers that provide dialysis.
Is it Good for All Kidney Failure Patients?
In fact, it is not suitable for all the patients because it requires a higher blood flow rate to be effective. Existing hemodialysis machines are not designed to deliver high-dose hemodiafiltration.For more information, please watch this video, also requested to subscribe our channel.
